Filing Flows › Bicycle Therapeutics (BCYC) › Q1 2026
Bicycle Therapeutics (BCYC) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 30, 2026
Bicycle Therapeutics (BCYC) reported revenue of $887K for the first quarter 2026 (Q1 2026), -91% from a year earlier and -98% from the quarter before.
Bicycle Therapeutics, Q1 2026: revenue $887K (-91% year over year), net loss $60.8M, operating cash flow −$65.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $887K | -98% | -91% |
| Operating profit | −$65.5M | — | — |
| Net earnings | −$60.8M | — | — |
| Operating cash flow | −$65.9M | — | — |
What changed
Revenue was $887K in Q1 2026, down 91% year over year and down 98% from the previous quarter.
Operating costs exceeded revenue by $65.5M, an operating margin of -7382.4%. Total costs fell 17% while revenue fell 91%. The quarter ended with a net loss of $60.8M, wider than the previous quarter's $20.2M loss.
Operating cash flow was −$65.9M. Non-cash charges added back $1.1M of depreciation and amortization and $6.9M of share-based compensation. Working capital and other items used $13.2M. Capital expenditures of $713K exceeded it, leaving free cash flow of −$66.6M.
Questions
What was Bicycle Therapeutics' revenue in the first quarter 2026?
Bicycle Therapeutics (BCYC) reported revenue of $887K for the first quarter 2026 (Q1 2026), -91% from a year earlier and -98% from the quarter before.